

PHARMACEUTICAL 2019



INTEGRATED BIOPHARMA INC Rank 281 of 363







PHARMACEUTICAL 2019



INTEGRATED BIOPHARMA INC Rank 281 of 363

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 203% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 213% points.

The company's Economic Capital Ratio, given in the ranking table, is -48%, being 85% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	12,154
Cost of Goods Sold	38,722
Intangible Assets	0
Liabilities, Current	16,180
Liabilities, Non-Current	3,624
Other Assets	763
Other Compr. Net Income	0
Other Expenses	326
Other Liabilities	0
Other Net Income	-689
Other Revenues	43,710
Property and Equipment	1,651
Research and Development	0
Selling, General and Administrative Expense	3,294

Output Variable	Value in 1000 USD
Assets	14,568
Liabilities	19,804
Expenses	42,342
Revenues	43,710
Stockholders Equity	-5,236
Net Income	679
Comprehensive Net Income	679
Economic Capital Ratio	-48%

